title: Macular Hole Progression following Ocriplasmin Intravitreal Injection.
abstract: Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.
authors.affiliation: Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK ; Moorfields Eye Hospital, London EC1V 2PD, UK.
authors.forename: Edward
authors.initials: E
authors.lastname: Casswell
authors.affiliation: Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Fernandez-Sanz
authors.affiliation: Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK.
authors.forename: Danny
authors.initials: D
authors.lastname: Mitry
authors.affiliation: Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK.
authors.forename: Sheila
authors.initials: S
authors.lastname: Luk
authors.affiliation: Department of Ophthalmology, Western Eye Hospital, London NW1 5QH, UK.
authors.forename: Rahila
authors.initials: R
authors.lastname: Zakir